CWC
AMPH icon

Carolinas Wealth Consulting’s Amphastar Pharmaceuticals AMPH Stock Holding History

Carolinas Wealth Consulting’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33
Closed -$1.59K – 1057
2024
Q3 		$1.59K Hold
33
– – ﹤0.01% 851
2024
Q2 		$1.31K Hold
33
– – ﹤0.01% 868
2024
Q1 		$1.44K Hold
33
– – ﹤0.01% 836
2023
Q4 		$2.02K Hold
33
– – ﹤0.01% 736
2023
Q3 		$1.48K Hold
33
– – ﹤0.01% 773
2023
Q2 		$1.88K Buy
+33
New +$1.46K ﹤0.01% 823

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Carolinas Wealth Consulting's AMPH Position: Q4 2024 in Review

Carolinas Wealth Consulting sold out of Amphastar Pharmaceuticals (AMPH) in Q4 2024, closing a stake of 33 shares — an estimated $1.59K sold.

Carolinas Wealth Consulting first reported a position in AMPH in Q2 2023 and held it in 6 quarters. The position peaked at $2.02K in Q4 2023. 263 funds tracked by Wall St. Rank hold AMPH as of Q4 2024.

  • Carolinas Wealth Consulting reported no remaining Amphastar Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Carolinas Wealth Consulting sold 33 Amphastar Pharmaceuticals shares in Q4 2024, an estimated $1.59K.
  • Carolinas Wealth Consulting first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Carolinas Wealth Consulting's Amphastar Pharmaceuticals position peaked at $2.02K in Q4 2023.
  • 263 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q4 2024.

Based on Carolinas Wealth Consulting's 13F filing for Q4 2024, filed 27 Feb 2025.